| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 25 | 2021 | 474 | 5.970 |
Why?
|
| Receptors, Adrenergic, beta-1 | 9 | 2019 | 22 | 3.000 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2021 | 65 | 2.210 |
Why?
|
| Receptors, Adrenergic, beta-2 | 8 | 2014 | 23 | 2.110 |
Why?
|
| Postural Orthostatic Tachycardia Syndrome | 4 | 2021 | 9 | 2.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2018 | 11 | 1.720 |
Why?
|
| Receptor, Muscarinic M2 | 5 | 2021 | 15 | 1.190 |
Why?
|
| Hypotension, Orthostatic | 3 | 2013 | 8 | 1.170 |
Why?
|
| Receptors, LHRH | 4 | 2021 | 17 | 1.110 |
Why?
|
| Insulin Resistance | 3 | 2021 | 176 | 1.050 |
Why?
|
| Autoimmunity | 3 | 2018 | 156 | 1.010 |
Why?
|
| Heart Rate | 5 | 2021 | 379 | 0.930 |
Why?
|
| Immunoglobulin G | 7 | 2013 | 270 | 0.930 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2015 | 163 | 0.840 |
Why?
|
| Atrial Fibrillation | 5 | 2015 | 403 | 0.840 |
Why?
|
| Rabbits | 8 | 2019 | 276 | 0.830 |
Why?
|
| Animals | 25 | 2021 | 10416 | 0.760 |
Why?
|
| Vasoconstriction | 4 | 2018 | 45 | 0.740 |
Why?
|
| Posture | 2 | 2019 | 39 | 0.730 |
Why?
|
| Muscarinic Antagonists | 1 | 2021 | 14 | 0.730 |
Why?
|
| Hypertension | 4 | 2015 | 309 | 0.720 |
Why?
|
| Myocardial Infarction | 4 | 2009 | 346 | 0.690 |
Why?
|
| Proteasome Inhibitors | 3 | 2009 | 26 | 0.690 |
Why?
|
| Graves Disease | 3 | 2015 | 8 | 0.690 |
Why?
|
| Peptide Fragments | 2 | 2019 | 202 | 0.690 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 1462 | 0.680 |
Why?
|
| Tachycardia | 3 | 2015 | 72 | 0.670 |
Why?
|
| Peptides | 3 | 2021 | 289 | 0.660 |
Why?
|
| Heart Diseases | 2 | 2010 | 70 | 0.610 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2009 | 80 | 0.600 |
Why?
|
| Hyperaldosteronism | 3 | 2014 | 3 | 0.600 |
Why?
|
| Blood Pressure | 2 | 2019 | 355 | 0.570 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 2011 | 24 | 0.530 |
Why?
|
| Vasodilator Agents | 2 | 2013 | 79 | 0.500 |
Why?
|
| Thyroxine | 1 | 2015 | 11 | 0.490 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2015 | 5 | 0.490 |
Why?
|
| Heart Atria | 2 | 2015 | 176 | 0.480 |
Why?
|
| Vasodilation | 3 | 2014 | 114 | 0.460 |
Why?
|
| Obesity | 1 | 2021 | 668 | 0.460 |
Why?
|
| Tachycardia, Ventricular | 2 | 2005 | 60 | 0.460 |
Why?
|
| Rats | 7 | 2021 | 1568 | 0.450 |
Why?
|
| Female | 17 | 2021 | 15192 | 0.440 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2014 | 23 | 0.440 |
Why?
|
| Thyroid Hormones | 1 | 2014 | 36 | 0.430 |
Why?
|
| Male | 20 | 2019 | 13511 | 0.430 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 33 | 0.420 |
Why?
|
| Ubiquitin | 2 | 2009 | 24 | 0.400 |
Why?
|
| Humans | 22 | 2021 | 28168 | 0.390 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2012 | 4 | 0.380 |
Why?
|
| Receptors, Muscarinic | 1 | 2011 | 9 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 329 | 0.370 |
Why?
|
| Arterioles | 4 | 2015 | 61 | 0.340 |
Why?
|
| Protease Inhibitors | 2 | 2009 | 40 | 0.330 |
Why?
|
| Cardiomyopathies | 2 | 2008 | 33 | 0.330 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2010 | 19 | 0.320 |
Why?
|
| Cytokines | 2 | 2021 | 446 | 0.300 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 73 | 0.300 |
Why?
|
| Cushing Syndrome | 1 | 2007 | 4 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 258 | 0.260 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 48 | 0.260 |
Why?
|
| Middle Aged | 11 | 2014 | 7164 | 0.260 |
Why?
|
| Dogs | 7 | 2010 | 509 | 0.250 |
Why?
|
| Critical Illness | 1 | 2007 | 68 | 0.250 |
Why?
|
| Renin | 2 | 2005 | 3 | 0.250 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2007 | 96 | 0.250 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2009 | 117 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 544 | 0.240 |
Why?
|
| Renal Artery Obstruction | 1 | 2005 | 4 | 0.240 |
Why?
|
| Renal Artery | 1 | 2005 | 15 | 0.240 |
Why?
|
| Adult | 9 | 2018 | 7765 | 0.230 |
Why?
|
| Aged | 7 | 2014 | 5417 | 0.220 |
Why?
|
| Biological Assay | 3 | 2021 | 35 | 0.220 |
Why?
|
| Blood Glucose | 2 | 2021 | 311 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 248 | 0.210 |
Why?
|
| Postoperative Complications | 1 | 2007 | 613 | 0.190 |
Why?
|
| Epitopes | 2 | 2021 | 179 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 66 | 0.180 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2021 | 18 | 0.180 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2021 | 4 | 0.180 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2021 | 23 | 0.180 |
Why?
|
| Testosterone | 1 | 2021 | 70 | 0.170 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2021 | 62 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 136 | 0.170 |
Why?
|
| Autoimmune Diseases | 2 | 2014 | 164 | 0.160 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 2 | 2009 | 7 | 0.160 |
Why?
|
| Young Adult | 3 | 2018 | 2738 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2021 | 184 | 0.160 |
Why?
|
| Hemodynamics | 2 | 2014 | 220 | 0.150 |
Why?
|
| Immunization | 1 | 2019 | 120 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 330 | 0.150 |
Why?
|
| Cricetinae | 3 | 2014 | 130 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2015 | 2384 | 0.150 |
Why?
|
| Signal Transduction | 2 | 2015 | 1433 | 0.140 |
Why?
|
| Losartan | 2 | 2014 | 4 | 0.140 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 8 | 0.140 |
Why?
|
| Cricetulus | 2 | 2014 | 56 | 0.130 |
Why?
|
| CHO Cells | 2 | 2014 | 97 | 0.130 |
Why?
|
| Adolescent | 3 | 2018 | 3128 | 0.130 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2008 | 28 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 634 | 0.130 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2015 | 4 | 0.120 |
Why?
|
| Muscarinic Agonists | 1 | 2015 | 9 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 608 | 0.120 |
Why?
|
| Coronary Sinus | 1 | 2015 | 4 | 0.120 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 2015 | 21 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Antibodies, Blocking | 1 | 2015 | 3 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2014 | 724 | 0.120 |
Why?
|
| Purkinje Fibers | 3 | 2010 | 37 | 0.120 |
Why?
|
| Antigens | 1 | 2015 | 67 | 0.120 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 20 | 0.120 |
Why?
|
| Electrocardiography | 3 | 2008 | 394 | 0.120 |
Why?
|
| Angiotensin II | 1 | 2015 | 55 | 0.120 |
Why?
|
| Atropine | 2 | 2012 | 47 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 245 | 0.110 |
Why?
|
| Propranolol | 2 | 2012 | 39 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 131 | 0.110 |
Why?
|
| Heart Conduction System | 1 | 2015 | 270 | 0.110 |
Why?
|
| Receptors, Adrenergic | 1 | 2014 | 10 | 0.110 |
Why?
|
| Captopril | 2 | 2005 | 9 | 0.110 |
Why?
|
| Myocardium | 2 | 2005 | 192 | 0.110 |
Why?
|
| Propanolamines | 1 | 2013 | 16 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 207 | 0.110 |
Why?
|
| Acetylcholine | 1 | 2013 | 73 | 0.110 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 77 | 0.110 |
Why?
|
| Surface Plasmon Resonance | 1 | 2013 | 37 | 0.100 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 60 | 0.100 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 38 | 0.100 |
Why?
|
| Autophagy | 1 | 2013 | 71 | 0.100 |
Why?
|
| Muscle Contraction | 1 | 2014 | 170 | 0.100 |
Why?
|
| Aorta | 1 | 2013 | 124 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 250 | 0.100 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2012 | 96 | 0.100 |
Why?
|
| Ligation | 3 | 2008 | 40 | 0.090 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2008 | 33 | 0.090 |
Why?
|
| Cardiac Myosins | 2 | 2008 | 17 | 0.090 |
Why?
|
| Electrophysiology | 3 | 2008 | 150 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 128 | 0.090 |
Why?
|
| Comorbidity | 1 | 2012 | 257 | 0.090 |
Why?
|
| Mitochondria | 1 | 2013 | 366 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1327 | 0.080 |
Why?
|
| Boronic Acids | 2 | 2008 | 9 | 0.080 |
Why?
|
| Bortezomib | 2 | 2008 | 22 | 0.080 |
Why?
|
| Pyrazines | 2 | 2008 | 24 | 0.080 |
Why?
|
| Syndrome | 2 | 2007 | 78 | 0.080 |
Why?
|
| Inflammation | 1 | 2013 | 633 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 76 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2013 | 663 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2009 | 191 | 0.070 |
Why?
|
| Myocarditis | 1 | 2008 | 21 | 0.070 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Adrenocortical Hyperfunction | 1 | 2007 | 3 | 0.070 |
Why?
|
| Aminoglutethimide | 1 | 2007 | 3 | 0.070 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 8 | 0.070 |
Why?
|
| Itraconazole | 1 | 2007 | 9 | 0.070 |
Why?
|
| Gastroplasty | 1 | 2007 | 5 | 0.070 |
Why?
|
| Streptozocin | 1 | 2007 | 11 | 0.070 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2007 | 11 | 0.070 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 29 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2008 | 513 | 0.070 |
Why?
|
| Mitochondria, Heart | 1 | 2007 | 23 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2007 | 63 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2007 | 64 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 115 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 225 | 0.060 |
Why?
|
| Body Weight | 1 | 2007 | 252 | 0.060 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 1 | 2005 | 3 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2006 | 108 | 0.060 |
Why?
|
| Diuresis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Furosemide | 1 | 2005 | 7 | 0.060 |
Why?
|
| Renal Veins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Diuretics | 1 | 2005 | 12 | 0.060 |
Why?
|
| Angiography | 1 | 2005 | 35 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 56 | 0.060 |
Why?
|
| Autonomic Nervous System | 1 | 2006 | 112 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 32 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Etanercept | 1 | 2005 | 6 | 0.060 |
Why?
|
| Pericardium | 1 | 2005 | 47 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 18 | 0.060 |
Why?
|
| Neutrophil Infiltration | 1 | 2005 | 19 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 113 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 123 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 327 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 163 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 181 | 0.050 |
Why?
|
| Kidney | 1 | 2005 | 286 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 826 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 1573 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2005 | 1149 | 0.050 |
Why?
|
| Follicular Atresia | 1 | 2021 | 4 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 2021 | 57 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2021 | 37 | 0.040 |
Why?
|
| Myocardial Contraction | 2 | 2009 | 62 | 0.040 |
Why?
|
| Mice | 1 | 2007 | 4655 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 2021 | 0.030 |
Why?
|
| Coronary Vessels | 2 | 2008 | 152 | 0.030 |
Why?
|
| Adrenergic Agonists | 1 | 2014 | 6 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Tennessee | 1 | 2014 | 27 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 463 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 318 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 494 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 763 | 0.020 |
Why?
|
| Oklahoma | 1 | 2014 | 1005 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2008 | 72 | 0.020 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 2008 | 4 | 0.020 |
Why?
|
| Catecholamines | 1 | 2008 | 18 | 0.020 |
Why?
|
| Trypsin | 1 | 2008 | 24 | 0.020 |
Why?
|
| Pheochromocytoma | 1 | 2007 | 9 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 56 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 56 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 200 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2007 | 114 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2008 | 137 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 690 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1052 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 372 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 123 | 0.020 |
Why?
|
| Aldosterone | 1 | 2002 | 4 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 1593 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 2558 | 0.010 |
Why?
|